Skip to Content
Merck
All Photos(1)

Documents

SML2860

Sigma-Aldrich

Triptorelin acetate

≥98% (HPLC)

Synonym(s):

6-D-Tryptophan-Luteinizing Hormone-Releasing Factor acetate, [D-Trp6]-LH-RH acetate

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C64H82N18O13 · xC2H4O2
Molecular Weight:
1311.45 (free base basis)
UNSPSC Code:
12352200
NACRES:
NA.77

Quality Level

100

Assay

≥98% (HPLC)

form

powder

color

white to off-white

storage temp.

−20°C

Biochem/physiol Actions

Triptorelin acetate is a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH). It is used clinically to treat prostate cancer and precocious puberty in boys and girls.

Pictograms

Health hazard
GHS08

Signal Word

Danger

Hazard Statements

H360D

Hazard Classifications

Repr. 1B

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Successful desensitization to gonadotropin-releasing hormone analogue triptorelin acetate using a sustained-release depot preparation.
Pauline Chan Ng et al.
Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 29(6), 660-663 (2018-05-29)
Delphine Zenaty et al.
Hormone research in paediatrics, 86(3), 188-195 (2016-11-02)
To evaluate the efficacy and safety of a triptorelin pamoate (11.25 mg) 3-month formulation in the management of central precocious puberty (CPP) (TP Study) and to retrospectively compare it with a triptorelin acetate (11.25 mg) 3-month formulation (TA Study). We
Davide Meani et al.
Therapeutic advances in urology, 10(2), 51-63 (2018-02-13)
Androgen deprivation therapy (ADT) with luteinizing hormone-releasing hormone (LHRH) agonists is well established for the treatment of men with metastatic prostate cancer. As clear differences in efficacy, safety, or tolerability between the available LHRH agonists are lacking, the healthcare management

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service